Trade Summary

2 days ago, Nagendran Sukumar, serving as President and Head of R&D at Taysha Gene Therapies, Inc. (TSHA), sold 200,000 shares at $6.24 per share, for a total transaction value of $1,248,000.00. Following this transaction, Nagendran Sukumar now holds 936,410 shares of TSHA.

This sale represents a 17.60% decrease in Nagendran Sukumar's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, July 10, 2026 and publicly disclosed via SEC Form 4 filing on Friday, July 10, 2026 at 6:54 PM ET, meaning the disclosure happened on the same day as the trade.

Taysha Gene Therapies, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.